Combination of intensive chemotherapy and imatinib (IDEAMOP regimen) for the treatment of newly diagnosed BCR-ABL positive acute lymphoblastic leukemia; Excellent efficacy without increasing toxicity.

被引：0
|
作者：
Yanada, M
Emi, N
Usui, N
Takeuchi, J
Sugiura, I
Takeuchi, M
Kobayashi, T
Yagasaki, F
Ohtake, S
Matsuo, K
Naoe, T
Ohno, R
机构：
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2736
引用
收藏
页码：748A / 748A
页数：1
相关论文
共 50 条
  • [21] Combination Chemotherapy With Tyrosine Kinase Inhibitors Can Overcome Bcr-Abl Mutations In Acute Lymphoblastic Leukemia Or Blast Crisis CML
    Benjamini, Ohad
    Kantarjian, Hagop M.
    O'Brien, Susan
    Thomas, Deborah
    Ravandi, Farhad
    Jain, Preetesh
    Pierce, Sherry
    Borthakur, Gautam
    Kadia, Tapan M.
    Jabbour, Elias
    Estrov, Zeev
    Luthra, Rajyalakshmi
    Cortes, Jorge E.
    BLOOD, 2013, 122 (21)
  • [22] The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment
    Thomas, Xavier
    Heiblig, Mael
    EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (11) : 1061 - 1070
  • [23] Allogeneic hematopoietic stem cell transplantation after combination therapy with imatinib and intensive chemotherapy for newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia.
    Usui, N
    Yano, S
    Takahara, S
    Asai, O
    Dobashi, N
    Osawa, H
    Takei, Y
    Ogasawara, Y
    Otubo, H
    Yamaguchi, Y
    Saito, T
    Minami, J
    Kaito, K
    Kobayashi, M
    BLOOD, 2005, 106 (11) : 410B - 411B
  • [24] Mechanisms of BCR-ABL leukemogenesis and novel targets for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia
    Platanias, Leonidas C.
    LEUKEMIA & LYMPHOMA, 2011, 52 : 2 - 3
  • [25] Comparison of clinical efficacy between first-generation and second-generation tyrosine kinase inhibitors based regimen in the treatment of patients with BCR-ABL positive acute lymphoblastic leukemia
    刘莹
    ChinaMedicalAbstracts(InternalMedicine), 2019, 36 (04) : 230 - 230
  • [26] Imatinib mesylate treatment induces stable disease but not remission in an animal model for human BCR/ABL positive acute lymphoblastic leukemia
    Nijmeijer, B
    Van Schie, M
    Melo, J
    Willemze, R
    Falkenburg, F
    EXPERIMENTAL HEMATOLOGY, 2003, 31 (07) : 150 - 151
  • [27] Toxicity of Intensive Chemotherapy in Association With Imatinib in Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia: French Experience of the Esphall Trial
    Probert, J.
    Schmitt, C.
    Petit, A.
    Carausu, L.
    Baruchel, A.
    Thouvenin-Doulet, S.
    Millot, F.
    Lutun, A.
    Bottolier-Colomb, E.
    Bertrand, Y.
    Plat-Willson, G.
    Simon, P.
    Deparis, M.
    Kanold, J.
    Plantaz, D.
    Nelken, B.
    Oudot, C.
    Sirvent, N.
    Schneider, P.
    Blouin, P.
    Valsecchi, M. Grazia
    Biondi, A.
    Gandemer, V.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S252 - S253
  • [28] Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
    Lim, Sung-Nam
    Joo, Young-Don
    Lee, Kyoo-Hyung
    Kim, Dae-Young
    Lee, Je-Hwan
    Lee, Jung-Hee
    Chi, Hyun-Sook
    Yun, Sung-Cheol
    Lee, Won Sik
    Lee, Sang Min
    Park, Seonyang
    Kim, Inho
    Sohn, Sang Kyun
    Moon, Joon Ho
    Ryoo, Hun-Mo
    Bae, Sung Hwa
    Hyun, Myung Soo
    Kim, Min Kyoung
    Kim, Hyeoung Joon
    Yang, Deok-Hwan
    Eom, Hyeon-Seok
    Lee, Gyeong-Won
    Jung, Chul Won
    Won, Jong-Ho
    Kim, Hawk
    Lee, Jae-Hoon
    Shin, Ho-Jin
    Jang, Dae-Young
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (11) : 1013 - 1020
  • [29] THE IMMUNOMODULATORY AGENT FTY720 INDUCES APOPTOSIS AND INHIBITS GROWTH OF BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND OVERCOMES IMATINIB RESISTANCE IN VITRO
    Schmidt-Tanguy, A.
    Badura, S.
    Nijmeijer, B. A.
    Wystub, S.
    Romanski, A.
    Ottmann, O. G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 249 - 250
  • [30] Leptomycin B overcomes imatinib resistance mediated by stromal cells and mutant BCR-ABL in Philadelphia chromosome-positive acute lymphoblastic leukemia cells.
    Tojo, A
    Izawa, K
    Sekine, R
    Nagamura, T
    Yoshida, M
    Tsuji, T
    BLOOD, 2004, 104 (11) : 575A - 575A
12345